{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:15:17Z","timestamp":1763705717514,"version":"3.44.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004320","name":"Shiraz University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.amjms.2020.01.011","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T02:21:31Z","timestamp":1579746091000},"page":"212-217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Acarbose versus Repaglinide in Diabetes Treatment: A New Appraisal of Two Old Rivals"],"prefix":"10.1016","volume":"359","author":[{"given":"Reza","family":"Pishdad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parisa","family":"Pishdad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gholam Reza","family":"Pishdad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjms.2020.01.011_bib0001","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2337\/dc11-0632","article-title":"Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes","volume":"34","author":"Riddle","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjms.2020.01.011_bib0002","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1475-2840-8-23","article-title":"Postprandial hyperglycemia as an etiological factor in vascular failure","volume":"8","author":"Node","year":"2009","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.amjms.2020.01.011_bib0003","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/eurheartj\/ehv239","article-title":"Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes","volume":"36","author":"Ferrannini","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjms.2020.01.011_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000439364","article-title":"Treatment goals in diabetes","volume":"31","author":"Melmer","year":"2016","journal-title":"Endocr Dev"},{"key":"10.1016\/j.amjms.2020.01.011_bib0005","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.2174\/1568026616666160414123500","article-title":"Important aspects of post-prandial antidiabetic drug, acarbose","volume":"16","author":"Singla","year":"2016","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.amjms.2020.01.011_bib0006","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2217\/pgs.14.152","article-title":"Pharmacogenomics of glinides","volume":"16","author":"Chen","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.amjms.2020.01.011_bib0007","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.amjms.2016.01.019","article-title":"Type 2 diabetes medication review","volume":"351","author":"Sterrett","year":"2016","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.amjms.2020.01.011_bib0008","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/1060028014558289","article-title":"Pharmacologic treatment of type 2 diabetes: oral medications","volume":"49","author":"Tran","year":"2015","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.amjms.2020.01.011_bib0009","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.mcna.2016.03.014","article-title":"Pharmacologic therapy of type 2 diabetes","volume":"4","author":"Wright","year":"2016","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.amjms.2020.01.011_bib0010","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s13300-016-0188-5","article-title":"Effective utilization of oral hypoglycemic agents to achieve individualized HbA1C targets in patients with type 2 diabetes mellitus","volume":"7","author":"Bannister","year":"2016","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.amjms.2020.01.011_bib0011","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4103\/0976-0105.121653","article-title":"Evaluation of antidiabetic prescriptions, cost and adherence to treatment guidelines: a prospective, cross-sectional study at a tertiary care teaching hospital","volume":"4","author":"Acharya","year":"2013","journal-title":"J Basic Clin Pharm"},{"key":"10.1016\/j.amjms.2020.01.011_bib0012","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF03345682","article-title":"The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese type 2 diabetic patients","volume":"32","author":"Duran","year":"2009","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.amjms.2020.01.011_bib0013","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1185\/03007990802711024","article-title":"Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial","volume":"25","author":"Derosa","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.amjms.2020.01.011_bib0014","doi-asserted-by":"crossref","first-page":"72700","DOI":"10.18632\/oncotarget.20282","article-title":"Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.amjms.2020.01.011_bib0015","first-page":"137","article-title":"Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose\/repaglinide application","volume":"17","author":"Rosak","year":"2004","journal-title":"Diabetes Nutr Metab"},{"key":"10.1016\/j.amjms.2020.01.011_bib0016","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.ijcard.2016.11.022","article-title":"Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: a nationwide study","volume":"228","author":"Lee","year":"2017","journal-title":"Int J Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.amjms.2020.01.011_bib0017","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4158\/EP.12.S1.25","article-title":"Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial","volume":"12","author":"Chiasson","year":"2006","journal-title":"Endocr Pract"},{"key":"10.1016\/j.amjms.2020.01.011_bib0018","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/14740338.2016.1195368","article-title":"Cardiovascular effects of anti-diabetes drugs","volume":"15","author":"Younk","year":"2016","journal-title":"Expert Opin Drug Saf"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962920300380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962920300380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:37:05Z","timestamp":1757702225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962920300380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0002962920300380"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2020.01.011","relation":{},"ISSN":["0002-9629"],"issn-type":[{"type":"print","value":"0002-9629"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acarbose versus Repaglinide in Diabetes Treatment: A New Appraisal of Two Old Rivals","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2020.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}